OP
OPKO Health, Inc.
OPK · NASDAQ
$1.61 +0.94% (+$0.02)
1M +18.38%
Market Cap $1.20B
P/E Ratio -
Div. Yield -
ROE 5.88%
Bulios Fair Price
$1.5
6.8% downside
Current Price
$1.61
Undervalued Fair Value Overvalued
According to Bulios Fair Price, OPK is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
39 /100
Fair EV/EBITDA 27.83x
P/S 2.04x
P/B 1.01x
Growth
0 /100
Declining Rev. growth 15.45%
Book val. growth 6.71%
EPS growth N/A
Profitability
11 /100
Weak Gross margin 30.98%
Net margin 12.40%
FCF margin 22.80%
Quality
4 /100
Poor ROIC 8.04%
ROE 5.88%
Asset turnover 0.32x
Debt
66 /100
Moderate Debt/Equity 0.33x
Current ratio 3.35x
Net debt/EBITDA 1.97x
Stability
39 /100
Moderate Beta 1.50x
Rev. volatility 1.76%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about OPK
Online
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Phillip Frost
Employees
2,275
Headquarters
Miami
Upcoming events
04 NOV
Earnings
Upcoming earnings report